CN113056286B - 用于治疗胰腺炎的方法 - Google Patents

用于治疗胰腺炎的方法 Download PDF

Info

Publication number
CN113056286B
CN113056286B CN201980073543.7A CN201980073543A CN113056286B CN 113056286 B CN113056286 B CN 113056286B CN 201980073543 A CN201980073543 A CN 201980073543A CN 113056286 B CN113056286 B CN 113056286B
Authority
CN
China
Prior art keywords
pancreatitis
antibody
markers
amino acid
pancreatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980073543.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN113056286A (zh
Inventor
D·D·恩格莱
D·A·图维森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cold Spring Harbor Laboratory
Original Assignee
Cold Spring Harbor Laboratory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Laboratory filed Critical Cold Spring Harbor Laboratory
Priority to CN202510438979.9A priority Critical patent/CN120267815A/zh
Publication of CN113056286A publication Critical patent/CN113056286A/zh
Application granted granted Critical
Publication of CN113056286B publication Critical patent/CN113056286B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201980073543.7A 2018-09-10 2019-09-09 用于治疗胰腺炎的方法 Active CN113056286B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510438979.9A CN120267815A (zh) 2018-09-10 2019-09-09 用于治疗胰腺炎的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862729354P 2018-09-10 2018-09-10
US62/729,354 2018-09-10
PCT/US2019/050262 WO2020055768A1 (en) 2018-09-10 2019-09-09 Methods for treating pancreatitis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510438979.9A Division CN120267815A (zh) 2018-09-10 2019-09-09 用于治疗胰腺炎的方法

Publications (2)

Publication Number Publication Date
CN113056286A CN113056286A (zh) 2021-06-29
CN113056286B true CN113056286B (zh) 2025-04-29

Family

ID=69776851

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980073543.7A Active CN113056286B (zh) 2018-09-10 2019-09-09 用于治疗胰腺炎的方法
CN202510438979.9A Pending CN120267815A (zh) 2018-09-10 2019-09-09 用于治疗胰腺炎的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510438979.9A Pending CN120267815A (zh) 2018-09-10 2019-09-09 用于治疗胰腺炎的方法

Country Status (13)

Country Link
US (1) US12378320B2 (cg-RX-API-DMAC7.html)
EP (1) EP3849605A4 (cg-RX-API-DMAC7.html)
JP (1) JP7560445B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210073515A (cg-RX-API-DMAC7.html)
CN (2) CN113056286B (cg-RX-API-DMAC7.html)
AU (1) AU2019337564A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021004444A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112382A1 (cg-RX-API-DMAC7.html)
CL (2) CL2021000585A1 (cg-RX-API-DMAC7.html)
IL (1) IL281343A (cg-RX-API-DMAC7.html)
MX (1) MX2021002761A (cg-RX-API-DMAC7.html)
SG (1) SG11202102416SA (cg-RX-API-DMAC7.html)
WO (1) WO2020055768A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020055768A1 (en) 2018-09-10 2020-03-19 Cold Spring Harbor Laboratory Methods for treating pancreatitis
US20250297027A1 (en) * 2021-01-12 2025-09-25 Yeda Research And Development Co. Ltd. Antibodies to cancer glycosylation and uses thereof
CA3214598A1 (en) * 2021-03-26 2022-09-29 BioNTech SE Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer
US12661076B2 (en) * 2024-03-26 2026-06-23 Hepatiq, Inc. Determining pancreas disease using functional imaging

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0274264A1 (en) * 1986-12-24 1988-07-13 FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. Reverse passive particle agglutination reagent
CN102137681A (zh) * 2008-08-08 2011-07-27 埃姆诺医药有限公司 抗胰腺癌抗体

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4471057A (en) * 1981-06-30 1984-09-11 The Wistar Institute Detection of colorectal carcinoma
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
US7238715B2 (en) 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
EP1924276A4 (en) 2005-08-05 2009-07-22 Araim Pharmaceuticals Inc Antiperspirant peptides and their uses
FI20070853A0 (fi) 2007-11-09 2007-11-09 Glykos Finland Oy Glykaania sitovat monoklonaaliset vasta-aineet
WO2009094172A2 (en) 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
PL2970422T3 (pl) 2013-03-15 2018-09-28 F.Hoffmann-La Roche Ag Polipeptydy IL-22 i białka fuzyjne IL-22 Fc i sposoby zastosowania
CN105517561A (zh) 2013-07-17 2016-04-20 阿拉伊姆药品公司 预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物
CN105764526B (zh) 2013-08-26 2020-12-15 生物技术研发公司 编码抗唾液酸化路易斯a抗原的人抗体的核酸
CN104623639A (zh) 2013-11-07 2015-05-20 健能隆医药技术(上海)有限公司 白介素22二聚体在制备治疗胰腺炎药物中的应用
RS60593B1 (sr) 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
WO2020055768A1 (en) 2018-09-10 2020-03-19 Cold Spring Harbor Laboratory Methods for treating pancreatitis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0274264A1 (en) * 1986-12-24 1988-07-13 FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. Reverse passive particle agglutination reagent
CN102137681A (zh) * 2008-08-08 2011-07-27 埃姆诺医药有限公司 抗胰腺癌抗体

Also Published As

Publication number Publication date
JP7560445B2 (ja) 2024-10-02
EP3849605A1 (en) 2021-07-21
AU2019337564A1 (en) 2021-05-06
CA3112382A1 (en) 2020-03-19
CL2021000585A1 (es) 2021-08-13
WO2020055768A1 (en) 2020-03-19
BR112021004444A2 (pt) 2021-06-01
JP2022500382A (ja) 2022-01-04
EP3849605A4 (en) 2022-06-15
CL2022000091A1 (es) 2022-11-18
CN120267815A (zh) 2025-07-08
KR20210073515A (ko) 2021-06-18
US20220049011A1 (en) 2022-02-17
US12378320B2 (en) 2025-08-05
IL281343A (en) 2021-04-29
MX2021002761A (es) 2021-05-31
SG11202102416SA (en) 2021-04-29
CN113056286A (zh) 2021-06-29

Similar Documents

Publication Publication Date Title
JP2022025071A (ja) グリコシル化pd-1に対して特異的な抗体およびその使用方法
EP3360571B1 (en) Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
JP7560445B2 (ja) 膵炎を処置するための方法
KR20090039748A (ko) 암의 치료, 진단 또는 검출을 위한 amigo-2 억제제
CN121248782A (zh) 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
AU2016261770B2 (en) Compounds and compositions useful for treating or preventing cancer metastasis, and methods using same
CN109563154B (zh) 抗帕多瓦因子ix抗体
JP2019505477A (ja) Btn1a1に免疫特異的に結合する抗体及び分子並びにそれらの治療的使用
US9790503B2 (en) VHZ for diagnosis and treatment of cancer
JP5756014B2 (ja) がんの診断および治療のためのvhz
CN111051346A (zh) 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
KR20180042423A (ko) Cd37 의 검출을 위한 항체 및 검정
JP2017526916A (ja) 癌の診断
JP2026063048A (ja) がん免疫微小環境の調節物質およびそれによる予防・診断・治療的利用
JP2021531007A (ja) Vistaに対する受容体
JP2023523145A (ja) リポ蛋白(a)に対するイソ型非依存性抗体
US20220289840A1 (en) Antibodies To Cell Adhesion Molecule-Related/Down-Regulated By Oncogenes (CDON) And Uses Thereof
TW202246354A (zh) 抗烯醇化酶1(eno1)抗體及其應用
US20250236683A1 (en) Composition and method for inhibiting fibrosis
RU2839356C2 (ru) Способы лечения панкреатита
WO2025217258A1 (en) Nptx1 antibodies
WO2025184480A2 (en) Antibodies to cell adhesion molecule-related/down-regulated by oncogenes (cdon) and uses thereof
HK40114573A (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
Hinkofer Distinction of vasculitis-associated ANCA subsets and their pathogenic role in a new mouse model with the humanized target antigen
HK1252633B (en) Antibodies binding to an intracellular prl-1 or prl-3 polypeptide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant